Edition:
United States

NxStage Medical Inc (NXTM.O)

NXTM.O on Nasdaq

27.45USD
11:47am EDT
Change (% chg)

$0.01 (+0.04%)
Prev Close
$27.44
Open
$27.50
Day's High
$27.66
Day's Low
$27.41
Volume
132,319
Avg. Vol
1,261,675
52-wk High
$30.80
52-wk Low
$20.45

Latest Key Developments (Source: Significant Developments)

NxStage Medical announces FDA clearance for solo home hemodialysis using NxStage system one
Monday, 28 Aug 2017 08:00am EDT 

Aug 28 (Reuters) - NxStage Medical Inc :NxStage Medical announces FDA clearance for solo home hemodialysis using NxStage® system one™.NxStage Medical Inc - ‍FDA has cleared its system one for solo home hemodialysis, without a care partner, during waking hours​.  Full Article

Nxstage Medical Inc says subsidiary is partnering with Dialyze Direct​
Friday, 11 Aug 2017 09:41am EDT 

Aug 11 (Reuters) - Nxstage Medical Inc :‍Nxstage kidney care subsidiary is partnering with Dialyze Direct​.  Full Article

NxStage Medical says if merger terminated, Fresenius Medical Care Holdings to pay termination fee of $100 mln- SEC Filing
Monday, 7 Aug 2017 04:53pm EDT 

Aug 7 (Reuters) - NxStage Medical Inc :NxStage Medical - if merger agreement terminated under certain circumstances,Fresenius Medical Care Holdings to pay co a termination fee of $100 million.  Full Article

NxStage Medical posts Q2 loss of $0.03 per share
Monday, 7 Aug 2017 02:15am EDT 

Aug 7 (Reuters) - Nxstage Medical Inc :NxStage reports second quarter financial results.Q2 revenue $96.2 million versus I/B/E/S view $96.5 million.NxStage Medical - in light of acquisition agreement between Fresenius Medical Care and NxStage, NxStage is no longer providing financial guidance.Has canceled its previously announced conference call to discuss its financial results for Q2 of 2017.Qtrly loss per share $0.03.  Full Article

NxStage Q1 revenue $96.8 million
Tuesday, 9 May 2017 08:16am EDT 

May 9 (Reuters) - NxStage Medical Inc ::NxStage reports first quarter financial results.Sees q2 2017 revenue $95 million to $97 million.Q1 revenue $96.8 million versus I/B/E/S view $95.3 million.NxStage Medical Inc - qtrly loss per share $ 0.02.NxStage Medical Inc - revising annual home revenue growth target to be between 10 to 13 pct for 2017 versus previous 15 pct target.NxStage Medical Inc - expect fy total company revenue in a range of $400 to $405 million.NxStage Medical Inc - company reaffirms total revenue guidance and profitability for 2017.NxStage Medical Inc - for q2 of 2017, company expects net loss in range of $1 to $3 million.Q2 revenue view $98.5 million -- Thomson Reuters I/B/E/S.Fy2017 revenue view $401.5 million -- Thomson Reuters I/B/E/S.Q1 earnings per share view $-0.02 -- Thomson Reuters I/B/E/S.  Full Article

NxStage reports Q4 revenue of $93 million
Tuesday, 28 Feb 2017 08:02am EST 

NxStage Medical Inc : NxStage reports fourth quarter and full-year 2016 financial results . Q4 revenue $93 million versus I/B/E/S view $91.8 million . Sees FY 2017 revenue $400 million to $405 million . NxStage Medical Inc - Company continues to target introduction of peritoneal dialysis system at end of 2017 . NxStage Medical Inc - Company is forecasting revenue between $95 and $97 million for Q1 of 2017 . NxStage Medical Inc - Company also expects to have positive net income for full fiscal year 2017 . Qtrly loss per share $0.02 . NxStage Medical Inc - Sees net loss in range of $1 to $3 million for Q1 of 2017 . Q4 earnings per share view $-0.02 -- Thomson Reuters I/B/E/S .FY2017 revenue view $401.2 million -- Thomson Reuters I/B/E/S.  Full Article

NxStage Medical Inc raises FY 2015 guidance; gives Q4 2015 guidance
Tuesday, 3 Nov 2015 07:28am EST 

NxStage Medical Inc:Expects FY 2015 revenue to be between $332 and $333 million, versus its previously increased guidance for revenue to be at the high end of its range of $324 to $328 million.Now expects FY 2015 net loss to be between $15 and $16 million, versus its previous guidance of $18 to $20 million, which was revised from its original guidance of $20 to $24 million.For the Q4 2015, the Company expects revenue to be in a range of $86 and $87 million, and a net loss in the range of $2 to $3 million.FY 2015 revenue of $327.8 million and net loss of $(20.1) million - Thomson Reuters I/B/E/S.Q4 2015 revenue of $85.9 million and net loss of $(3.71) million - Thomson Reuters I/B/E/S.  Full Article

BRIEF-NxStage Medical announces FDA clearance for solo home hemodialysis using NxStage system one

* NxStage Medical announces FDA clearance for solo home hemodialysis using NxStage® system one™